Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VI-1121 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo/VI-1121 | EXPERIMENTAL | Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period. |
| VI-1121/Placebo | EXPERIMENTAL | Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period. |
| Name | Type | Description |
|---|---|---|
| VI-1121 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * clinical diagnosis of Alzheimer's disease * CT or MRI within 2 years prior to study * stable dose of current Alzheimer's treatment for at least 3 months Exclusion Criteria: * advanced, severe, progressive or unstable disease * history of cerebrovascular disease or myocardial...
Top 20 of 23 competitors